11-108252858-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The NM_000051.4(ATM):c.1844T>C(p.Leu615Pro) variant causes a missense change. The variant allele was found at a frequency of 0.00000274 in 1,460,860 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.1844T>C | p.Leu615Pro | missense_variant | Exon 12 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000274 AC: 4AN: 1460860Hom.: 0 Cov.: 30 AF XY: 0.00000275 AC XY: 2AN XY: 726776
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:2Uncertain:1
- -
It is not observed in the gnomAD v2.1.1 dataset (PM2). The variant was observed in trans with a pathogenic variant [NM_000051.3:c.8687A>C (p.Gln2896Pro)] as compound heterozygous (3billion dataset, PM3). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.792, PP3). Patient's phenotype is considered compatible with Ataxia-telangiectasia (3billion dataset, PP4). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline -
This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 615 of the ATM protein (p.Leu615Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with ataxia-telangiectasia and/or prostate cancer (PMID: 29368341, 30549301, 32901917; internal data). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 187501). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Familial cancer of breast Pathogenic:2
- -
The ATM c.1844T>C (p.Leu615Pro) missense change is absent in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). This variant has been observed in trans with a pathogenic variant [NM_000051.3:c.8687A>C (p.Gln2896Pro)] in at least one patient with ataxia telangiectasia (PMID: 26896183, 30549301, 32901917). ATM expression and ATM activity assays performed on a lymphoblastoid cell line derived from the patient’s blood demonstrated residual kinase activity. In addition, the in silico tool REVEL predicts a deleterious effect on protein function. This variant is absent in a database of women older than 70 years of age who have never had cancer (FLOSSIES database, https://whi.color.com/). In summary, this variant meets criteria to be classified as likely pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1Uncertain:1
The p.L615P variant (also known as c.1844T>C), located in coding exon 11 of the ATM gene, results from a T to C substitution at nucleotide position 1844. The leucine at codon 615 is replaced by proline, an amino acid with similar properties. This variant was identified in conjunction with other pathogenic variants in ATM in multiple individuals diagnosed with ataxia-telangiectasia (Schon K et al. Ann Neurol 2019 02;85(2):170-180; Seo GH et al. Clin Genet 2020 12;98(6):562-570). This amino acid position is highly conserved in available vertebrate species. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
This missense variant replaces leucine with proline at codon 615 of the ATM protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been observed in the compound heterozygous state in an individual affected with autosomal recessive variant ataxia-telangiectasia (PMID: 26896183, 30549301), indicating that this variant contributes to disease. This variant has been reported in trans with a variant of uncertain significance, c.8687A>C (p.Gln2896Pro), in a second individual affected with ataxia-telangiectasia (PMID: 32901917). In addition, this variant has been observed in individuals affected with prostate cancer (PMID: 29368341). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Pathogenic:1
Identified in an individual with prostate cancer (PMID: 29368341); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32901917, 30549301, 29368341, 26896183) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at